Literature DB >> 11978336

Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial.

Harm van Tinteren1, Otto S Hoekstra, Egbert F Smit, Jan H A M van den Bergh, Ad J M Schreurs, Roland A L M Stallaert, Piet C M van Velthoven, Emile F I Comans, Fred W Diepenhorst, Paul Verboom, Johan C van Mourik, Pieter E Postmus, Maarten Boers, Gerrit J J Teule.   

Abstract

BACKGROUND: Up to 50% of curative surgery for suspected non-small-cell lung cancer is unsuccessful. Accuracy of positron emission tomography (PET) with 18-fluorodeoxyglucose (18FDG) is thought to be better than conventional staging for diagnosis of this malignancy. Up to now however, there has been no evidence that PET leads to improved management of patients in routine clinical practice. We did a randomised controlled trial in patients with suspected non-small-cell lung cancer, who were scheduled for surgery after conventional workup, to test whether PET with 18FDG reduces number of futile thoracotomies.
METHODS: Before surgery (mediastinoscopy or thoracotomy), 188 patients from nine hospitals were randomly assigned to either conventional workup (CWU) or conventional workup and PET (CWU+PET). Patients were followed up for 1 year. Thoracotomy was regarded as futile if the patient had benign disease, explorative thoracotomy, pathological stage IIIA-N2/IIIB, or postoperative relapse or death within 12 months of randomisation. The primary outcome measure was futile thoracotomy. Analysis was by intention to treat.
FINDINGS: 96 patients were randomly assigned CWU and 92 CWU+PET. Two patients in the CWU+PET group did not undergo PET. 18 patients in the CWU group and 32 in the CWU+PET group did not have thoracotomy. In the CWU group, 39 (41%) patients had a futile thoracotomy, compared with 19 (21%) in the CWU+PET group (relative reduction 51%, 95% CI 32-80%; p=0.003).
INTERPRETATION: Addition of PET to conventional workup prevented unnecessary surgery in one out of five patients with suspected non-small-cell lung cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11978336     DOI: 10.1016/s0140-6736(02)08352-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  128 in total

1.  Do we need randomised trials to evaluate diagnostic procedures? For.

Authors:  H Van Tinteren; O S Hoekstra; M Boers
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-11-29       Impact factor: 9.236

2.  Are health technology assessments a reliable tool in th analysis of the clinical value of PET in oncology? Who audits the auditors?

Authors:  Liselotte Højgaard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05       Impact factor: 9.236

3.  The need for Health Technology Assessments of PET.

Authors:  H Van Tinteren; O S Hoekstra; M Boers
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-07-31       Impact factor: 9.236

4.  Potential benefits of using a toolkit developed to aid in the adaptation of HTA reports: a case study considering positron emission tomography (PET) and Hodgkin's disease.

Authors:  Sheila Turner; Neil Adams; Andrew Cook; Alison Price; Ruairidh Milne
Journal:  Health Res Policy Syst       Date:  2010-05-26

5.  Advanced imaging and hospice use in end-of-life cancer care.

Authors:  Michaela A Dinan; Lesley H Curtis; Soko Setoguchi; Winson Y Cheung
Journal:  Support Care Cancer       Date:  2018-05-04       Impact factor: 3.603

6.  FDG PET-CT SUVmax and IASLC/ATS/ERS histologic classification: a new profile of lung adenocarcinoma with prognostic value.

Authors:  Marina Suárez-Piñera; José Belda-Sanchis; Alvaro Taus; Albert Sánchez-Font; Antoni Mestre-Fusco; Marcel Jiménez; Lara Pijuan
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-04-25

Review 7.  Positron emission tomography to assess hypoxia and perfusion in lung cancer.

Authors:  Eline E Verwer; Ronald Boellaard; Astrid Am van der Veldt
Journal:  World J Clin Oncol       Date:  2014-12-10

Review 8.  PET in the management of locally advanced and metastatic NSCLC.

Authors:  Willem Grootjans; Lioe-Fee de Geus-Oei; Esther G C Troost; Eric P Visser; Wim J G Oyen; Johan Bussink
Journal:  Nat Rev Clin Oncol       Date:  2015-04-28       Impact factor: 66.675

9.  Using pet-ct to reduce futile thoracotomy rates in non-small-cell lung cancer: a population-based review.

Authors:  M Smoragiewicz; J Laskin; D Wilson; K Ramsden; J Yee; S Lam; T Shaipanich; Y Zhai; C Ho
Journal:  Curr Oncol       Date:  2014-12       Impact factor: 3.677

10.  The usefulness of combined diagnostic CT and (99m)Tc-octreotide somatostatin receptor SPECT/CT imaging on pulmonary nodule characterization in patients.

Authors:  Liwei Wang; Xindao Yin; Feng Wang; Jianping Gu; Lingquan Lu; Qianzhi Wu; Baozhong Shen; Xiao-Feng Li
Journal:  Cancer Biother Radiopharm       Date:  2013-10-05       Impact factor: 3.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.